+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Global Multiple Sclerosis Therapeutics Market (By Region - North America (The US), Europe & Asia Pacific) Outlook 2025

  • ID: 4807951
  • Report
  • Region: Global, Asia, Asia Pacific, Europe, North America, United States
  • 83 Pages
  • Rockville Research
1 of 3

FEATURED COMPANIES

  • Bayer AG
  • Biogen Inc.
  • Novartis AG
  • Pfizer Inc
  • Sanofi Genzyme
  • Teva Pharmaceuticals
  • MORE

Global multiple sclerosis treatment markets have been witnessing fast strides with various new drugs in the late-stage pipeline. Recently, Novartis approved FDA approval for Mayzent, the first and only treatment specifically approved for patients with active secondary progressive multiple sclerosis (SPMS). The drug is expected to address the critical unmet need of multiple sclerosis patients belonging to varied disease categories.

The report “Global Multiple Sclerosis Therapeutics Market (By Region - North America (The US), Europe & Asia Pacific) Outlook 2025” provides an in-depth analysis of global multiple sclerosis market with a focus on major markets in regions such as North America, Europe & Asia Pacific.

The report provides comprehensive coverage on major industry drivers, restraints, and their impact on market growth during the forecast period. Furthermore, the study encompasses various market specific growth opportunities in the global multiple sclerosis market. The report has been segmented as follows:

Geographical Coverage

  • North America - The US
  • Europe
  • Asia Pacific

Key Vendors

  • Biogen Inc.
  • Teva Pharmaceuticals
  • Bayer AG
  • Sanofi Genzyme
  • Novartis AG
  • Pfizer Inc.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Bayer AG
  • Biogen Inc.
  • Novartis AG
  • Pfizer Inc
  • Sanofi Genzyme
  • Teva Pharmaceuticals
  • MORE

1. Executive Summary

2. Research Methodology

3. Multiple Sclerosis
3.1 Overview
3.1.1 Symptoms of MS
3.2 Types of MS
3.3 Treatment

4. Market Analysis
4.1 Market Sizing (Actual & Forecasted)
4.2 Market Share Analysis
4.2.1 Market Share by Type
4.2.2 Market Share by Mode of Administration
4.2.3 Market Share by Drug Class
4.2.4 Market Share by Region

5. Drug Analysis

6. Regional Analysis
6.1 North America
6.1.1 Market Sizing (Actual & Forecasted)
6.1.2 The US
6.1.2.1  Market Sizing (Actual & Forecasted)
6.1.2.2  Market Share by Products
6.2 Europe
6.2.1 Market Sizing (Actual & Forecasted)
6.3 Asia Pacific
6.3.1 Market Sizing (Actual & Forecasted)

7. Market Dynamics
7.1 Industry Trends & Developments
7.1.1 Drug Modifying Therapies for MS
7.1.2 Launch of New Drugs
7.1.3 Drugs Price Hike
7.2 Growth Drivers
7.2.1 Increasing Prevalence of Multiple Sclerosis
7.2.2 Ageing Population
7.2.3 Robust Drug Pipeline
7.2.4 Rising Healthcare Expenditure
7.2.5 Growth in per Capita Income
7.3 Challenges
7.3.1 Patent Expiration of Major Drugs
7.3.2 Stringent Regulatory Norms
7.3.3 Expensive Drugs
7.3.4 Side-effects of Drugs

8. Competitive Landscape
8.1 Product Landscape
8.2 Financial Analysis
8.3 Market Share Analysis

9. Company Profiles
9.1 Biogen Inc.
9.2 Teva Pharmaceuticals
9.3 Bayer AG
9.4 Sanofi Genzyme
9.5 Novartis AG
9.6 Pfizer Inc.

List of Tables and Figures
Figure 1: Research Methodology
Figure 2: Diagrammatic Representation of Multiple Sclerosis
Figure 3: Progression of Multiple Sclerosis
Figure 4: Global Multiple Sclerosis Market Size by Value, 2011-18 (US$ Billions)
Figure 5: Global Multiple Sclerosis Market Size by Value, Forecasted 2019E-25E (US$ Billions)
Figure 6: Global Multiple Sclerosis Therapeutics Market Share by Type (2018)
Figure 7: Global Multiple Sclerosis Therapeutics Market Share by Mode of Drug Administration (2018)
Figure 8: Global Multiple Sclerosis Therapeutics Market Share by Drug Class (2018)
Figure 9: Global Multiple Sclerosis Market Share by Region (2018)
Table 1: Multiple Sclerosis Drug Analysis
Table 2: Multiple Sclerosis Injectable Treatment
Table 3: Multiple Sclerosis Oral Treatment
Table 4: Multiple Sclerosis Intravenous Infusion Treatment
Figure 10: North America Multiple Sclerosis Market Size by Value, 2018-25E (US$ Billions)
Figure 11: The US Multiple Sclerosis Market Size by Value, 2018-25E (US$ Billions)
Figure 12: The US Multiple Sclerosis Therapeutics Market Share by Products (2018)
Figure 13: Europe Multiple Sclerosis Market Size by Value, 2018-25E (US$ Billions)
Figure 14: Asia Pacific Multiple Sclerosis Market Size by Value, 2018-25E (US$ Billions)
Table 5: Drug Modifying Therapies for Multiple Sclerosis
Figure 15: Multiple Sclerosis Prevalence by Nations, 2015 (per 100,000 people)
Figure 16: Global Ageing (65 Years and above) Population, 2013-18 (Millions)
Figure 17: Age-Standardized Prevalence of Multiple Sclerosis, by Age & Sex (2017)
Table 6: Multiple Sclerosis Drug Pipeline
Figure 18: Global Healthcare Expenditure, 2014-19E (US$ Billions)
Figure 19: Global per Capita Income, 2014-19E (US$)
Figure 20: Global Multiple Sclerosis Therapeutics Market - Impact of New Launches & Patent Expirations
Table 7: Multiple Sclerosis Drugs Price Hike
Table 8: Multiple Sclerosis Drugs - Cost per additional QALY
Table 9: Multiple Sclerosis Products - Competitive Landscape
Table 10: Global Multiple Sclerosis Companies Financial Analysis (FY2018)
Table 11: Leading Multiple Sclerosis Products Sales Forecast, FY2017-FY2022E (US$ Millions)
Figure 21: Global Multiple Sclerosis Therapeutics Market Share by Drugs (2018)
Figure 22: Biogen Inc. Revenue by Products (FY2018)
Table 12: Biogen Inc. Multiple Sclerosis Drugs & Major Markets
Figure 23: Biogen Inc. Multiple Sclerosis Products Revenue, FY2016-FY2018 (US$ Millions)
Figure 24: Biogen Inc. Net Sales, FY2014-FY2019E (US$ Billions)
Figure 25: Teva Pharmaceuticals Revenue by Business Segment (FY2018)
Table 13: Teva Pharmaceuticals Multiple Sclerosis Drugs
Figure 26: Teva Pharmaceuticals Net Sales, FY2015-FY2019E (US$ Billions)
Figure 27: Bayer AG Revenue by Business Segment (FY2018)
Table 14: Bayer AG Multiple Sclerosis Drugs
Figure 28: Bayer AG Net Sales, FY2015-FY2019E (US$ Billions)
Figure 29: Sanofi Aventis Revenue by Business Segment (FY2018)
Table 15: Sanofi Genzyme Multiple Sclerosis R&D Pipeline
Figure 30: Sanofi Aventis Net Sales, FY2015-FY2019E (US$ Billions)
Figure 31: Novartis AG Revenue by Business Segment (FY2018)
Table 16: Novartis AG Multiple Sclerosis R&D Pipeline
Figure 32: Novartis AG Net Sales, FY2015-FY2019E (US$ Billions)
Figure 33: Pfizer Inc. Revenue by Business Segment (FY2018)
Table 17: Pfizer Inc. Multiple Sclerosis R&D Pipeline
Figure 34: Pfizer Inc. Net Sales, FY2015-FY2019E (US$ Billions)

Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Bayer AG
  • Biogen Inc.
  • Novartis AG
  • Pfizer Inc
  • Sanofi Genzyme
  • Teva Pharmaceuticals
Note: Product cover images may vary from those shown
Adroll
adroll